Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Jacobio Pharmaceuticals Group Co., Ltd. has announced a reallocation of the net proceeds from its Global Offering, detailing changes in the utilization of funds across various projects, including clinical trials and commercialization activities in China. The company provided updated figures on the utilization and remaining unutilized net proceeds as of certain key dates in 2023. This adjustment reflects the company’s ongoing strategic financial management to enhance its research and development efforts and operational capabilities.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.
